首页> 美国卫生研究院文献>other >Microarray-Based Analysis of Methylation Status of CpGs in Placental DNA and Maternal Blood DNA – Potential New Epigenetic Biomarkers for Cell Free Fetal DNA-Based Diagnosis
【2h】

Microarray-Based Analysis of Methylation Status of CpGs in Placental DNA and Maternal Blood DNA – Potential New Epigenetic Biomarkers for Cell Free Fetal DNA-Based Diagnosis

机译:基于微阵列的胎盘DNA和母体血液DNA中CpG甲基化状态的分析-基于无细胞胎儿DNA的诊断的潜在新的表观遗传标记

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Epigenetic markers for cell free fetal DNA in the maternal blood circulation are highly interesting in the field of non-invasive prenatal testing since such markers will offer a possibility to quantify the amount of fetal DNA derived from different chromosomes in a maternal blood sample. The aim of the present study was to define new fetal specific epigenetic markers present in placental DNA that can be utilized in non-invasive prenatal diagnosis. We have conducted a high-resolution methylation specific beadchip microarray study assessing more than 450.000 CpG sites. We have analyzed the DNA methylation profiles of 10 maternal blood samples and compared them to 12 1st trimesters chorionic samples from normal placentas, identifying a number of CpG sites that are differentially methylated in maternal blood cells compared to chorionic tissue. To strengthen the utility of these differentially methylated CpG sites to be used with methyl-sensitive restriction enzymes (MSRE) in PCR-based NIPD, we furthermore refined the list of selected sites, containing a restriction sites for one of 16 different methylation-sensitive restriction enzymes. We present a list of markers on chromosomes 13, 18 and 21 with a potential for aneuploidy testing as well as a list of markers for regions harboring sub-microscopic deletion- or duplication syndromes.
机译:母体血液循环中无细胞胎儿DNA的表观遗传标记在非侵入性产前检测领域非常受关注,因为此类标记将提供量化母体血液样本中不同染色体衍生的胎儿DNA数量的可能性。本研究的目的是确定胎盘DNA中存在的新的胎儿特异性表观遗传标记,可用于非侵入性产前诊断。我们进行了高分辨率甲基化特异性珠芯片微阵列研究,评估了超过450.000 CpG位点。我们分析了10个母体血液样品的DNA甲基化谱图,并将它们与正常胎盘的12个1 s 三个月的绒毛膜样品进行了比较,确定了与绒毛膜蛋白相比,母体血细胞中甲基化程度不同的多个CpG位点组织。为了增强这些差异甲基化的CpG位点与基于PCR的NIPD中的甲基敏感性限制酶(MSRE)一起使用的效用,我们进一步完善了所选位点的列表,其中包含16个不同的甲基化敏感性限制位点之一的限制位点酶。我们提出了在染色体13、18和21上有可能进行非整倍性检测的标记物清单,以及存在亚显微缺失或复制综合征的区域的标记物清单。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号